Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST)
Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST)
Development and expansion of the IFOM-IEO campus
Histology and non-histology driven therapy for soft tissue sarcomas and the Rare Cancers Europe initiative
MET inhibitors for non-small cell lung cancer
Pathology and development of ovarian cancer
Putting the theory of personalised medicine into practice
Trametinib and dabrafenib combination therapy against metastatic melanoma
Personalised cancer medicine and research: Today’s best practice
Phase I study examining PI 3 kinase inhibitor for various tumours
Biomarker analysis of MISSION: EGFR lung tumours may benefit from sorafenib
iwNHL 10: Advances in the treatment of lymphoma
Molecular stratification of breast cancer: reaching the clinic